SavedAdd your journal

Journals / Kırıkkale Üniversitesi Tıp Fakültesi Dergisi / 2026 / Cilt: 24 Sayı: 1

QUANTITATIVE ASSESSMENT OF RENAL STEATOSIS AND ITS RELATIONSHIP WITH CLINICAL STAGE IN CHRONIC RENAL FAILURE USING CHEMICAL SHIFT MRI

Kronik Böbrek Hastalığında Renal Steatozun ve Klinik Evre ile İlişkisinin Kimyasal Şift MRG ile Kantitatif Olarak Değerlendirilmesi

Hüseyin Aydın(Süleyman Demirel Üniversitesi Tıp Fakültesi Radyoloji Anabilim Dalı)0000-0003-4704-4759
Abdulkerim Şalkacı(İnegöl Devlet Hastanesi)0000-0001-6578-8108
Adnan Karaibrahimoğlu(Süleyman Demirel Üniversitesi, Tıp Fakültesi, Biyoistatistik ve Tıbbi Bilişim ABD)0000-0002-8277-0281
Alper Dilli(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA DIŞKAPI YILDIRIM BEYAZIT SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, RADYOLOJİ ANABİLİM DALI)0000-0002-8057-9109
Pages
93–101
Publication Date
2022-04-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objective: Quantitative measurement of renal parenchymal lipid accumulation in chronic renal disease using chemical shift magnetic resonance imaging and evaluation of its relationship with clinical stages.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Quantitative measurement of renal parenchymal lipid accumulation in chronic renal disease using chemical shift magnetic resonance imaging and evaluation of its relationship with clinical stages.
📊
Key Findings & Data:Objective: Quantitative measurement of renal parenchymal lipid accumulation in chronic renal disease using chemical shift magnetic resonance imaging and evaluation of its relationship with clinical stages.
💡
Conclusion & Impact:Objective: Quantitative measurement of renal parenchymal lipid accumulation in chronic renal disease using chemical shift magnetic resonance imaging and evaluation of its relationship with clinical stages.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Manyetik rezonans görüntüleme · kronik böbek hastalığı · diabetes mellitus

Abstract

Objective: Quantitative measurement of renal parenchymal lipid accumulation in chronic renal disease using chemical shift magnetic resonance imaging and evaluation of its relationship with clinical stages.

Özet

Amaç: Kronik böbrek hastalığında renal parankimal lipid birikiminin kantitatif olarak kimyasal şift manyetik rezonans görüntüleme ile ölçülmesi ve klinik evreler ile ilişkisinin değerlendirilmesi amaçlandı

🔖

Cite This Article

Aydın, H., Şalkacı, A., Karaibrahimoğlu, A., Dilli, A. (2022). QUANTITATIVE ASSESSMENT OF RENAL STEATOSIS AND ITS RELATIONSHIP WITH CLINICAL STAGE IN CHRONIC RENAL FAILURE USING CHEMICAL SHIFT MRI. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi, Cilt: 24 Sayı: 1, 93–101. https://ajindex.com/articles/1215063

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (21)

  1. Druilhet RE, Overturf ML, Kirkendall WM. Structure of neutral glycerides and phosphoglycerides of human kidney. Int J Biochem. 1975;6(12):893-901.
  2. Bobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens. 2010;19(4):393.
  3. De Vries APJ, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2(5):417-26.
  4. Escasany E, Izquierdo-Lahuerta A, Medina-Gomez G. Underlying mechanisms of renal lipotoxicity in obesity. Nephron. 2019;143(1):29-33.
  5. Garofalo C, Borrelli S, Minutolo R, Chiodini P, De Nicola L, Conte G. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int. 2017;91(5):1224-35.
  6. Mende C, Einhorn D. Fatty kidney disease: The importance of ectopic fat deposition and the potential value of imaging. J Diabetes. 2022;14(1):73-8.
  7. Spit KA, Muskiet MHA, Tonneijck L, Smits MM, Kramer MHH, Joles JA et al. Renal sinus fat and renal hemodynamics: a cross-sectional analysis. Magn Reson Mater Physics, Biol Med. 2020;33(1):73-80.
  8. Mende CW, Einhorn D. Fatty kidney disease: A new renal and endocrine clinical entity? Describing the role of the kidney in obesity, metabolic syndrome, and type 2 diabetes. Endocr Pract. 2019;25(8):854-8.
  9. Yokoo T, Clark HR, Pedrosa I, Yuan Q, Dimitrov I, Zhang Y et al. Quantification of renal steatosis in type II diabetes mellitus using dixon‐based MRI. J Magn Reson Imaging. 2016;44(5):1312-9. 10. Dixon WT. Simple proton spectroscopic imaging. Radiology. 1984;153(1):189-94.
  10. Pretorius ES, Solomon JA. Radiology secrets plus E-book. Elsevier Health Sciences, 2010.
  11. Pacifico L, Nobili V, Anania C, Verdecchia P, Chiesa C. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol. 2011;17(26):3082.
  12. Sijens PE, Edens MA, Bakker SJL, Stolk RP. MRI-determined fat content of human liver, pancreas and kidney. World J Gastroenterol. 2010;16(16):1993.
  13. Moorhead JF, El-Nahas M, Chan MK, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982;320(8311):1309-11.
  14. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements. 2013;3(1):1-150.
  15. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-130.
  16. Outwater EK, Siegelman ES, Huang AB, Birnbaum BA. Adrenal masses: correlation between CT attenuation value and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences. Radiology. 1996;200(3):749-52.
  17. Hsu C, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21-8.
  18. Kim JJ, Wilbon SS, Fornoni A. Podocyte Lipotoxicity in CKD. Kidney360. 2021;2(4):755-62.
  19. Pei K, Gui T, Li C, Zhang Q, Feng H, Li Y et al. Recent progress on lipid intake and chronic kidney disease. Biomed Res Int. 2020;2020:3680397.
  20. Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72(4):785-801.
  21. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589-600.